The frequency and type of mutations in the EGFR gene of colorectal carcinoma patients in Southeastern Serbia

Dragana Jugović, Marija Vukelić Nikolić, Višnja Madić, Aleksandar Milićević, Perica Vasiljević

Abstract


Colorectal carcinoma (CRC) represents a global health problem. The EGFR signaling pathway is very important in the initiation of different human epithelial cancers and plays a key role in colorectal carcinogenesis. Considering the role of EGFR as a mitogenic inducer, this study aimed to determine the frequency and type of mutations in the EGFR gene and its correlation with  clinicopathological characteristics of patients with CRC on the territory of Southeastern Serbia. The genomic DNA of patients was isolated from formalin-fixed and paraffin-embedded tissues. The presence of mutations in exons 18, 19, 20, and 21 was determined by the Real-Time PCR method. The frequency of mutations in the EGFR gene in CRC patients of Southeastern Serbia was 7.9%. All detected mutations were G719X. No statistically significant correlation was found between mutational status in the EGFR gene and the  clinicopathological characteristics of patients.


Keywords


colorectal carcinoma, EGFR, mutations

Full Text:

PDF

References


Barber, T.D., Vogelstein, B., Kinzler, K.W., & Velculescu, V.E. (2004). Somatic mutations of EGFR in colorectal cancers and glioblastomas. New England Journal of Medicine, 351-2883.

Barnes, P., Yeboah, F.A., Zhu, J., Saahene, R.O., Obirikorang, C., Adinortey, M.B., Amoani, B., Kyei, F., Akakpo, P., & Awuku, Y.A. (2020). Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors. Journal of cancer epidemiology, 5615303.

Campos, F.G. (2017). Colorectal cancer in young adults: a difficult challenge. World Journal of Gastroenterology, 23, 5041.

Cho, J., Bass, A.J., Lawrence, M.S., Cibulskis, K. Cho, A., Lee, S.N., Yamauchi, M., Wagle, N., Pochanard, P., Kim, N., Park, A.K.J., Won, J., Hur, H.S., Greulich, H., Ogino, S., Sougnez, C., Voet, D., Tabernero, J., Jimenez, J., Baselga, J., Gabriel, S. B., Lander, E.S., Getz, G., Eck, M.J., Park, W.Y., & Meyerson, M. (2014). Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer, 13, 141.

Connel, L.C., Mota, J.M., Braghiroli, M.I., & Hoffa, P.M. (2017). The rising incidence of younger patients with colorectal cancer: questions about screening, biology and tretmant. Current treatment options in oncology, 18(4), 23.

del Carmen, S., Corchete, L.A., Gervas, R., Rodriguez, A., Garcia, M., Álcazar, J.A., García, J., Bengoechea, O., Muñoz-Bellvis, L., Sayagués, J.M., & Abad, M. (2020). Prognostic implications of EGFR protein expression in sporadic colorectal tumors: Correlation with copy number status, mRNA levels and miRNA regulation. Scientific Reports, 10, 4662.

Du, P., Xu, B., Zhang, D., Shao, Y., Zheng, X., Li, X., Xiong, Y., Wu, C., & Jiang, J. (2017). Hierarchical investigating the predictive value of p53, COX2, EGFR, nm23 in the post-operative patients with colorectal carcinoma. Oncotarget, 8(1), 954–966.

Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., & Bray, F. (2020). Global Cancer Observatory: Cancer Today. France, Lyon: International Agency for Research on Cancer.

Hao, M., Wang, K., Ding, Y., Li, H., Liu, Y., & Ding, L. (2022). Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer. European journal of medical research, 27(1), 130.

Hashmi, A.A., Hashmi, S.K., Irfan, M. Asif, H., Nisar, L., Naeem, M., Khan, E.Y., Baloch, S., & Farid, N. (2019). Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma. Applied Cancer Research, 39, 2.

Hirsh, V. (2018) Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Therapeutic advances in medical oncology, 10, 1758834017753338.

Institut za javno zdravlje Srbije „Dr Milan Jovanović Batut”. (2018). Malignant tumours in Republic of Serbia. Retrieved from https://www.batut.org.rs/download/publikacije/MaligniTumori2018.pdf

Ionescu, A., Bilteanu, L., Geicu, O.I., Iordache, F., Stanca, L., Pisoschi, A.M., Miron, A., Serban, A.I., & Calu, V. (2022). Multivariate Risk Analysis of RAS, BRAF and EGFR Mutations Allelic Frequency and Coexistence as Colorectal Cancer Predictive Biomarkers. Cancers, 14(11), 2792.

Kim, N., Cho, D., Kim, H., Kim, S., Cha, Y.J., Greulich, H., Bass, A., Cho, H.S., & Cho, J. (2020). Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. International journal of cancer, 146(8), 2194–2200.

Koveitypour, Z., Panahi, F., Vakilian, M., Peymani, M., Seyed Forootan, F., Nasr Esfahani, M.H., & Ghaedi, K. (2019). Signaling pathways involved in colorectal cancer progression. Cell & bioscience, 9, 97.

Liu, H., Zhang, B., & Sun, Z. (2020). Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun (Lond), 40(1), 43-59.

Liu, J., Zhou, Q., Xu, J., Wang, J., & Zhang, Y. (2016). Detection of EGFR expression in patients with colorectal cancer and the therapeutic effect of cetuximab. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 21(1), 95–100.

Mármol, I., Sánchez de Diego, C., Pradilla, D.A., Cerrada, E., & Rodriguez Yoldi, M.J. (2017). Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. International journal of molecular sciences, 18(1), 197.

Mendelsohn, J., Prewett, M., Rockwell, P., & Goldstein, N.I. (2015). CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth. Clinical Cancer Research, 21(2), 227–9.

Metzger, B., Chambeau, L., Begon, D.Y., Faber, C., Kayser, J., Berchem, G., Pauly, M., Boniver, J., Delvenne, P., Dicato, M., & Wenner, T. (2011). The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC medical genetics, 12, 144.

Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S.P., Minoche, A., Seshagiri, S., Serrano, S., Himmelbauer, H., Bellmunt, J., Rovira, A., Settleman, J., Bosch, F., & Albanell, J. (2012). Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nature medicine, 18(2), 221–223.

Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005). Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. The Lancet. Oncology, 6(5), 279–286.

Mosesson Y., Mills G.B., & Yarden, Y. (2008). Derailed endocytosis: An emerging feature of cancer. Nature reviews. Cancer, 8(11), 835–850.

Ogino, S., Meyerhardt, J.A., Cantor, M., Brahmandam, M., Clark, J.W., Namgyal, C., Kawasaki, T., Kinsella, K., Michelini, A.L., Enzinger, P.C., Kulke, M.H., Ryan, D.P., Loda, M., & Fuchs, C.S. (2005). Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 11(18), 6650–6656.

Oh, B.Y., Lee, R.A., Chung, S.S., & Kim, K.H. (2011). Epidermal growth factor receptor mutations in colorectal cancer patients. Journal of the Korean Society of Coloproctology, 27(3), 127–132.

Phua, L.C., Ng, H.W., Yeo, A.H., Chen, E., Lo, M.S., Cheah, P.Y., Chan, E.C., Koh, P.K., & Ho, H.K. (2015). Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. Oncology letters, 10(4), 2519–2526.

Porru, M., Pompili, L., Caruso, C., Biroccio, A., & Leonetti, C. (2018). Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. Journal of experimental & clinical cancer research: CR, 37(1), 57.

Randon, G., Yaeger, R., Hechtman, J.F., Manca, P., Fucà, G., Walch, H., Lee, J., Élez, E., Seligmann, J., Mussolin, B., Pagani, F., Germani, M.M., Ambrosini, M., Rossini, D., Ratti, M., Salvà, F., Richman, S.D., Wood, H., Nanjangud, G., Gloghini, A., Milione, M., Bardelli, A., De Braud, F., Morano, F., Cremolini, C., & Pietrantonio, F. (2021). EGFR Amplification in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 113(11), 1561–1569.

Ruhe, J.E., Streit, S., Hart, S., Wong, C.H., Specht, K., Knyazev, P., Knyazeva, T., Tay, L.S., Loo, H.L., Foo, P., Wong, W., Pok, S., Lim, S.J., Ong, H., Luo, M., Ho, H.K., Peng, K., Lee, T.C., Bezler, M., Mann, C., Gaertner, S., Hoefler, H., Iacobelli, S., Peter, S., Tay, A., Brenner, S., Venkatesh, B., & Ullrich, A. (2007). Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer research, 67(23), 11368–11376.

Saletti, P., Molinari, F., De Dosso, S., & Frattini, M. (2015). EGFR signaling in colorectal cancer: a clinical perspective. Gastrointestinal Cancer: Targets and Therapy, 5, 21-38.

Silva Rocha, F., da Silva Maués, J.H., Brito Lins Pereira, C.M., Moreira-Nunes, C.A., & Rodriguez Burbano, R.M. (2021). Analysis of Increased EGFR and IGF-1R Signaling and Its Correlation with Socio-Epidemiological Features and Biological Profile in Breast Cancer Patients: A Study in Northern Brazil. Breast Cancer (Dove Med Press), 13, 325-339.

Skřičková, J., Májková, P., Barinová, M., Bratová, M., Pešek, M., Svaton, M., Kolek, V., Fišer, O., Koubková, L., Benejová, A., Venclícek, O., Cernovská, M., Havel, L., Hrnciarik, M., Roubec, J., Milada, Z., Opálka, P., Krejcí, J., Krejcí, D., Coupková, H., & Merta, Z. (2020). Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry. European Respiratory Journal, 56(64), 1686.

Syrigos, K., Kotteas, I., Paraskeva, M., Gkiozos, I., Boura, P., Tsagouli, S., Grapsa, D., & Charpidou, A. (2018). Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer. European Respiratory Journal, 52, PA 2852.

Tanaka, T., Kaida, T., Yokoi, K., Ishii, S., Nishizawa, N., Kawamata, H., Katoh, H., Sato, T., Nakamura, T., Watanabe, M., & Yamashita, K. (2019). Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer. Oncology letters, 17(1), 1257–1266.

Tasdemir, S., Taheri, S., Akalin, H., Kontas, O., Onal, O., & Ozkul, Y. (2019). Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. The Eurasian journal of medicine, 51(2), 177–185.

Tong, G.J., Zhang, G.Y., Liu, J., Zheng, Z.Z., Chen, Y., Niu, P.P., & Xu, X.T. (2018). Comparison of the eighth version of the American Joint Committee on Cancer manual to the seventh version for colorectal cancer: A retrospective review of our data. World journal of clinical oncology, 9(7), 148–161.

Uhlyarik, A., Piurko, V., Papai, Z., Raso, E., Lahm, E., Kiss, E., Sikter, M., Vachaja, J., Kenessey, I., & Timar, J. (2020). EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy. Cancers, 12(3), 614.

Wang, D., Wang, B., Wang, R., Zhang, Z., Lin, Y., Huang, G., Lin, S., Jiang, Y., Wang, W., Wang, L., & Huang, Q. (2017). High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival. Oncology Letters, 13(5), 3003-3013.

Wee, P. & Wang, Z. (2017). Epidermal growth factor receptor cell proliferation signaling pathways. Cancers, 9(5), 52.

Zou, S.M., Li, W.H., Wang, W.M., Li, W.B., Shi, S.S., Ying, J.M., & Lyu, N. (2018). The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. Journal of cancer research and clinical oncology, 144(11), 2149–2159.


Refbacks

  • There are currently no refbacks.